Canadian Cancer Trials Group Bulletins

Trial Management Group


First Patient Enrolled onto Canadian Cancer Trials Group CX.5

Canadian Cancer Trials Group CX.5 -- A Randomized Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer -- recently enrolled its first patient!

Led by Canadian Cancer Trials Group, CX.5 will include participation from a number of international groups who are part of the Gynecologic Cancer Intergroup. The Principal Investigator of the trial is Dr. Marie Plante, and co-investigators include Tony Fyles, Peter Craighead, Gavin Stuart, Dongsheng Tu, Michael Brundage, Lori Brotto, Janice Kwon, Nicole Mittmann, Sarah Ferguson, Jocelyne Arseneau, Mostafa Atri, and Ralph Meyer.

This trial received $2.2M over 8 years from CIHR. The objective of this trial is to compare the outcome and quality of life between standard radical hysterectomy and nodes versus simple hysterectomy and nodes in low-risk disease. This work has the potential to be a groundbreaking and practice-changing study. The total number of patients will be 700.

If you would like more information about this trial, please contact Andrea Hiltz, Study Coordinator, at 613-533-6430 or ahiltz@ctg.queensu.ca.